Mary-Ann Lindsay Selected Research

Mary-Ann Lindsay Research Topics

12	Breast Neoplasms (Breast Cancer) 07/2015 - 04/2002
3	Neoplasms (Cancer) 03/2011 - 08/2002
2	Neutropenia 07/2015 - 10/2002
2	Cardiotoxicity 10/2011 - 10/2002
2	Febrile Neutropenia 10/2002 - 06/2002
1	Neoplasm Metastasis (Metastasis) 07/2015
1	Alopecia (Baldness) 07/2015
1	Stomatitis 07/2015
1	Heart Failure 10/2011
1	Leukemia 10/2011
1	Fatigue 04/2011
1	Hypertension (High Blood Pressure) 04/2011
1	Disease Progression 05/2004
1	Infections 06/2002

7	Trastuzumab (Herceptin)FDA Link 07/2015 - 06/2002
7	Docetaxel (Taxotere)FDA Link 01/2013 - 06/2002
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2013 - 06/2002
7	AnthracyclinesIBA 01/2013 - 06/2002
6	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2013 - 06/2002
3	Taxoids (Taxanes)IBA 10/2011 - 06/2002
2	Paclitaxel (Taxol)FDA LinkGeneric 07/2015 - 04/2011
2	Hormones (Hormone)IBA 07/2015 - 04/2011
2	taxaneIBA 01/2013 - 04/2011
2	Fluorouracil (Carac)FDA LinkGeneric 01/2013 - 08/2002
2	Carboplatin (JM8)FDA LinkGeneric 10/2011 - 05/2004
2	SaltsIBA 05/2004 - 06/2002
2	PlatinumIBA 05/2004 - 06/2002
1	Biological ProductsIBA 07/2015
1	Everolimus FDA Link 07/2015
1	benthiocarb (Bolero)IBA 07/2015
1	Alkylating AgentsIBA 10/2011
1	ErbB Receptors (EGF Receptor)IBA 10/2011
1	Bevacizumab (Avastin)FDA Link 04/2011
1	motesanib diphosphateIBA 04/2011
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2011
1	EnzymesIBA 03/2011
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 03/2011
1	Cisplatin (Platino)FDA LinkGeneric 05/2004
1	leridistimIBA 10/2002
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2002
1	Monoclonal AntibodiesIBA 10/2002
1	Filgrastim (Neupogen)FDA Link 10/2002
1	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 10/2002
1	myelopoietinIBA 10/2002
1	Methotrexate (Mexate)FDA LinkGeneric 08/2002
1	Proteins (Proteins, Gene)FDA Link 08/2002

6	Drug Therapy (Chemotherapy) 07/2015 - 08/2002
5	Therapeutics 07/2015 - 08/2002
2	Combination Drug Therapy (Combination Chemotherapy) 01/2013 - 04/2002
1	Neoadjuvant Therapy 04/2011
1	Molecular Targeted Therapy 08/2002